Sun Pharmaceutical Industries

Sun Pharma generates revenue through the manufacture and sale of generic and specialty pharmaceuticals across more than 100 countries. Its physical footprint of over 40 manufacturing sites is the core asset that produces returns through scale-driven cost advantages in production. As an operating company, investor returns flow through equity appreciation and dividends, not from management fees on pooled capital.

Dr. Abhishek Sharma is the named contact for institutional investors, operating from the corporate office in Mumbai's SUN HOUSE. The firm also maintains a Secretarial Department for individual investors and has appointed MUFG Intime India Private Limited as its registrar and transfer agent. Anoop Deshpande serves as Company Secretary and Compliance Officer, handling regulatory and grievance-related inquiries.

The firm maintains a specific business-development channel on its website, inviting external entities to 'partner with Sun Pharma.' This signals an active effort to in-license products or co-develop generics, which supplements its internal R&D pipeline. No specific transactions or partnership dollar figures are publicly disclosed through this channel.

The firm reports supplying medicines to more than 100 countries, with identifiable offices in Mumbai, Vadodara, and Halol, India, and an additional global headquarters presence in the United States. Localized in-country websites provide contact information for individual national operations, reflecting a decentralized distribution model that maps to local regulatory environments.